Cargando…
Exome-wide association study of levodopa-induced dyskinesia in Parkinson’s disease
Levodopa is the standard long-term dopamine replacement therapy to treat Parkinson’s disease (PD) symptoms. With time, levodopa may induce debilitating dyskinesias (LID), the treatment of which represents a large clinically unmet need. However, time-to-LID onset varies between patients, reflecting a...
Autores principales: | König, Eva, Nicoletti, Alessandra, Pattaro, Cristian, Annesi, Grazia, Melotti, Roberto, Gialluisi, Alessandro, Schwienbacher, Christine, Picard, Anne, Blankenburg, Hagen, Pichler, Irene, Modugno, Nicola, Ciullo, Marina, Esposito, Teresa, Domingues, Francisco S., Hicks, Andrew A., Zappia, Mario, Pramstaller, Peter P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486836/ https://www.ncbi.nlm.nih.gov/pubmed/34599261 http://dx.doi.org/10.1038/s41598-021-99393-8 |
Ejemplares similares
-
Analysis of Genetic and Non-genetic Predictors of Levodopa Induced Dyskinesia in Parkinson’s Disease
por: Tirozzi, Alfonsina, et al.
Publicado: (2021) -
Identification of a set of endogenous reference genes for miRNA expression studies in Parkinson’s disease blood samples
por: Serafin, Alice, et al.
Publicado: (2014) -
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
por: Luca, Antonina, et al.
Publicado: (2021) -
Profiling of Parkin-Binding Partners Using Tandem Affinity Purification
por: Zanon, Alessandra, et al.
Publicado: (2013) -
LOW DOSE LEVODOPA IN TARDIVE DYSKINESIA
por: Sethi, Sujata, et al.
Publicado: (1990)